Target Name: OR6A2
NCBI ID: G8590
Review Report on OR6A2 Target / Biomarker Content of Review Report on OR6A2 Target / Biomarker
OR6A2
Other Name(s): hP2 olfactory receptor | Olfactory receptor, family 6, subfamily A, member 1 | hI7 olfactory receptor | olfactory receptor 6A1 | OR6A1 | Olfactory receptor 6A1 | Olfactory receptor family 6 subfamily A member 2 | Olfactory receptor, family 6, subfamily A, member 2 | olfactory receptor 11-55 | olfactory receptor, family 6, subfamily A, member 2 pseudogene | olfactory receptor family 6 subfamily A member 2 | OR6A2P | Seven transmembrane helix receptor | olfactory receptor OR11-83 | Olfactory receptor, family 6, subfamily A, member 2 pseudogene | OR6A2_HUMAN | MGC126540 | Olfactory receptor OR11-83 | I7 | olfactory receptor, family 6, subfamily A, member 1 | MGC126538 | seven transmembrane helix receptor | Olfactory receptor 11-55 | OR11-55 | Olfactory receptor 6A2

OR6A2: A Potential Drug Target and Biomarker for Olfactory Receptor function

Olfactory receptors (ORs) are a family of transmembrane proteins that play a crucial role in human sensory function, specifically olfaction. ORs are composed of a perceptually active site, a transmembrane region, and an intracellular loop. They are involved in the perception of a wide variety of stimuli, including scents, flavors, and textures. ORs are also involved in the regulation of homeostasis, including the production and degradation of neurotransmitters, as well as the modulation of pain and anxiety responses.

hP2 olfactory receptor, also known as OR6A2, is a member of the OR family and is expressed in the olfactory cortical neurons of the brain. OR6A2 is involved in the perception of scents, and its function has been extensively studied in the context of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and chronic insomnia.

Recent studies have suggested that hP2 olfactory receptor may be a potential drug target for these diseases. By targeting hP2 OR6A2, researchers may be able to improve sensory function, reduce neurodegeneration, and improve overall quality of life in patients with these conditions.

One approach to targeting hP2 OR6A2 is through the use of small molecule inhibitors. These inhibitors can be designed to specifically bind to hP2 OR6A2 and prevent it from interacting with its downstream signaling pathways. One such inhibitor, NK-134, has been shown to inhibit the activity of hP2 OR6A2 and improve olfactory function in animal models of Alzheimer's disease.

Another approach to targeting hP2 OR6A2 is through the use of monoclonal antibodies (MCAs). MCAs are laboratory-produced antibodies that can be designed to specifically recognize and bind to a specific protein target. In the case of hP2 OR6A2, MCA-targeted antibodies have has been shown to be effective in animal models of neurodegenerative diseases.

In addition to drug targeting, hP2 OR6A2 may also be used as a biomarker for monitoring disease progression. By measuring the expression and function of hP2 OR6A2 in brain tissue, researchers can gain insight into the impact of different treatments on neurodegeneration and determine the effectiveness of new therapies.

In conclusion, hP2 olfactory receptor is a promising drug target and biomarker for the treatment of olfactory neurodegenerative diseases. The development of small molecule inhibitors and MCA-targeted antibodies may provide new avenues for the treatment of these conditions. Further research is needed to fully understand the role of hP2 OR6A2 in sensory function and its potential as a drug target and biomarker.

Protein Name: Olfactory Receptor Family 6 Subfamily A Member 2

Functions: Odorant receptor

The "OR6A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR6A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR6B1 | OR6B2 | OR6B3 | OR6C1 | OR6C2 | OR6C3 | OR6C4 | OR6C65 | OR6C70 | OR6C74 | OR6C75 | OR6C76 | OR6F1 | OR6J1 | OR6K2 | OR6K3 | OR6M1 | OR6N1 | OR6N2 | OR6P1 | OR6Q1 | OR6R2P | OR6S1 | OR6T1 | OR6W1P | OR6X1 | OR6Y1 | OR7A10 | OR7A17 | OR7A5 | OR7C1 | OR7C2 | OR7D1P | OR7D2 | OR7D4 | OR7E104P | OR7E109P | OR7E121P | OR7E122P | OR7E125P | OR7E13P | OR7E140P | OR7E14P | OR7E155P | OR7E156P | OR7E19P | OR7E22P | OR7E24 | OR7E25P | OR7E29P | OR7E37P | OR7E41P | OR7E47P | OR7E5P | OR7E62P | OR7E84P | OR7E85BP | OR7E87P | OR7E91P | OR7E94P | OR7G1 | OR7G2 | OR7G3 | OR7M1P | OR8A1 | OR8B12 | OR8B2 | OR8B3 | OR8B4 | OR8B6P | OR8B7P | OR8B8 | OR8D1 | OR8D2 | OR8D4 | OR8F1P | OR8G1 | OR8G2P | OR8G3P | OR8G5 | OR8G7P | OR8H1 | OR8H2 | OR8H3 | OR8I2 | OR8J1 | OR8J3 | OR8K1 | OR8K3 | OR8K5 | OR8S1 | OR8U1 | OR8U3 | OR8U8 | OR9A1P | OR9A2 | OR9A4 | OR9G1 | OR9G4 | OR9G9